Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Ercaliskan A , Eskazan AE . The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer. 2018;124(19):3806‐3818.29694669)
Ercaliskan A , Eskazan AE . The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer. 2018;124(19):3806‐3818.29694669Ercaliskan A , Eskazan AE . The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer. 2018;124(19):3806‐3818.29694669, Ercaliskan A , Eskazan AE . The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer. 2018;124(19):3806‐3818.29694669
( Brabander T , van der Zwan WA , Teunissen JJM , et al. Long‐term efficacy, survival, and safety of [177Lu‐DOTA0,Tyr3]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617‐4624.28428192)
Brabander T , van der Zwan WA , Teunissen JJM , et al. Long‐term efficacy, survival, and safety of [177Lu‐DOTA0,Tyr3]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617‐4624.28428192Brabander T , van der Zwan WA , Teunissen JJM , et al. Long‐term efficacy, survival, and safety of [177Lu‐DOTA0,Tyr3]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617‐4624.28428192, Brabander T , van der Zwan WA , Teunissen JJM , et al. Long‐term efficacy, survival, and safety of [177Lu‐DOTA0,Tyr3]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617‐4624.28428192
( Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogemous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290‐293.4126434)
Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogemous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290‐293.4126434Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogemous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290‐293.4126434, Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogemous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290‐293.4126434
( Kantarjian HM , Keating MJ , Walters RS , et al. Therapy‐related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4(12):1748‐1757.3783201)
Kantarjian HM , Keating MJ , Walters RS , et al. Therapy‐related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4(12):1748‐1757.3783201Kantarjian HM , Keating MJ , Walters RS , et al. Therapy‐related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4(12):1748‐1757.3783201, Kantarjian HM , Keating MJ , Walters RS , et al. Therapy‐related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4(12):1748‐1757.3783201
J. Goldman, J. Melo (2001)
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.The New England journal of medicine, 344 14
N. Iriyama, M. Tokuhira, T. Takaku, Eriko Sato, Maho Ishikawa, T. Nakazato, K. Sugimoto, H. Fujita, Isao Fujioka, Y. Hatta, M. Kizaki, N. Komatsu, N. Asou, T. Kawaguchi (2017)
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.Leukemia research, 54
H. Kantarjian, M. Keating, R. Walters, T. Smith, A. Cork, K. McCredie, E. Freireich (1986)
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4 12
( Garske‐Román U , Sandström M , Fröss Baron K , et al. Prospective observational study of 177Lu‐DOTA‐octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry‐guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970‐988.29497803)
Garske‐Román U , Sandström M , Fröss Baron K , et al. Prospective observational study of 177Lu‐DOTA‐octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry‐guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970‐988.29497803Garske‐Román U , Sandström M , Fröss Baron K , et al. Prospective observational study of 177Lu‐DOTA‐octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry‐guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970‐988.29497803, Garske‐Román U , Sandström M , Fröss Baron K , et al. Prospective observational study of 177Lu‐DOTA‐octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry‐guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970‐988.29497803
( Raymond E , Dahan L , Raoul JL , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501‐513.21306237)
Raymond E , Dahan L , Raoul JL , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501‐513.21306237Raymond E , Dahan L , Raoul JL , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501‐513.21306237, Raymond E , Dahan L , Raoul JL , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501‐513.21306237
Hendrik Bergsma, K. Lom, M. Konijnenberg, B. Kam, J. Teunissen, W. Herder, E. Krenning, D. Kwekkeboom (2017)
Therapy-related hematological malignancies after peptide receptor radionuclide therapy with 177Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETsThe Journal of Nuclear Medicine
H. Tsushima, M. Iwanaga, Y. Miyazaki (2012)
Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromesInternational Journal of Hematology, 95
( Aguiar RC . Therapy‐related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29(1–2):17‐26.9638972)
Aguiar RC . Therapy‐related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29(1–2):17‐26.9638972Aguiar RC . Therapy‐related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29(1–2):17‐26.9638972, Aguiar RC . Therapy‐related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29(1–2):17‐26.9638972
E. Lin, Tina Chen, Alana Little, Laura-Jane Holliday, P. Roach, P. Butler, Erika Hosking, E. Bailey, B. Elison, D. Currow (2019)
Safety and outcomes of 177Lu‐DOTATATE for neuroendocrine tumours: experience in New South Wales, AustraliaInternal Medicine Journal, 49
( Issa GC , Kantarjian HM , Gonzalez GN , et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome‐negative metaphases during CML treatment. Blood. 2017;130(19):2084‐2091.28835440)
Issa GC , Kantarjian HM , Gonzalez GN , et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome‐negative metaphases during CML treatment. Blood. 2017;130(19):2084‐2091.28835440Issa GC , Kantarjian HM , Gonzalez GN , et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome‐negative metaphases during CML treatment. Blood. 2017;130(19):2084‐2091.28835440, Issa GC , Kantarjian HM , Gonzalez GN , et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome‐negative metaphases during CML treatment. Blood. 2017;130(19):2084‐2091.28835440
R. Louis, S. Gupta, Sonal Jain, A. Mehta, M. Agarwal (2016)
Therapy Related Chronic Myeloid Leukemia (trCML) or non-Therapy Related Second Malignancy Chronic Myeloid Leukemia (smCML) following Diffuse Large B-Cell Lymphoma(DLBCL): A Case Report and Review of LiteratureAmerican Journal of Cancer Case Reports, 4
R. Aguiar (1998)
Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.Leukemia & lymphoma, 29 1-2
( Lin E , Chen T , Little A , et al. Safety and outcomes of 177Lu‐DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J. 2019;49(10):1268‐1277.31062490)
Lin E , Chen T , Little A , et al. Safety and outcomes of 177Lu‐DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J. 2019;49(10):1268‐1277.31062490Lin E , Chen T , Little A , et al. Safety and outcomes of 177Lu‐DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J. 2019;49(10):1268‐1277.31062490, Lin E , Chen T , Little A , et al. Safety and outcomes of 177Lu‐DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J. 2019;49(10):1268‐1277.31062490
( Goldman JM , Melo JV . Targeting the BCR‐ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084‐1086.11287980)
Goldman JM , Melo JV . Targeting the BCR‐ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084‐1086.11287980Goldman JM , Melo JV . Targeting the BCR‐ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084‐1086.11287980, Goldman JM , Melo JV . Targeting the BCR‐ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084‐1086.11287980
( Demirci E , Kabasakal L , Toklu T , et al. 177Lu‐DOTATATE therapy in patients with neuroendocrine tumours including high‐grade (WHO G3) neuroendocrine tumours: response to treatment and long‐term survival update. Nucl Med Commun. 2018;39(8):789‐796.29912750)
Demirci E , Kabasakal L , Toklu T , et al. 177Lu‐DOTATATE therapy in patients with neuroendocrine tumours including high‐grade (WHO G3) neuroendocrine tumours: response to treatment and long‐term survival update. Nucl Med Commun. 2018;39(8):789‐796.29912750Demirci E , Kabasakal L , Toklu T , et al. 177Lu‐DOTATATE therapy in patients with neuroendocrine tumours including high‐grade (WHO G3) neuroendocrine tumours: response to treatment and long‐term survival update. Nucl Med Commun. 2018;39(8):789‐796.29912750, Demirci E , Kabasakal L , Toklu T , et al. 177Lu‐DOTATATE therapy in patients with neuroendocrine tumours including high‐grade (WHO G3) neuroendocrine tumours: response to treatment and long‐term survival update. Nucl Med Commun. 2018;39(8):789‐796.29912750
B. Brieau, O. Hentic, R. Lebtahi, M. Palazzo, Makrem Reguiga, V. Rebours, F. Maire, P. Hammel, P. Ruszniewski, P. Fenaux (2016)
High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.Endocrine-related cancer, 23 5
Hendrik Bergsma, K. Lom, M. Raaijmakers, M. Konijnenberg, B. Kam, J. Teunissen, W. Herder, E. Krenning, D. Kwekkeboom (2018)
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine TumorsThe Journal of Nuclear Medicine, 59
( Brieau B , Hentic O , Lebtahi R , et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu‐octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17‐L23.26932783)
Brieau B , Hentic O , Lebtahi R , et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu‐octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17‐L23.26932783Brieau B , Hentic O , Lebtahi R , et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu‐octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17‐L23.26932783, Brieau B , Hentic O , Lebtahi R , et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu‐octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17‐L23.26932783
( Bergsma H , van Lom K , Raaijmakers MHGP , et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu‐DOTATATE: incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors. J Nucl Med. 2018;59(3):452‐458.28775205)
Bergsma H , van Lom K , Raaijmakers MHGP , et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu‐DOTATATE: incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors. J Nucl Med. 2018;59(3):452‐458.28775205Bergsma H , van Lom K , Raaijmakers MHGP , et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu‐DOTATATE: incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors. J Nucl Med. 2018;59(3):452‐458.28775205, Bergsma H , van Lom K , Raaijmakers MHGP , et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu‐DOTATATE: incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors. J Nucl Med. 2018;59(3):452‐458.28775205
( Louis R , Gupta SK , Jain S , Mehta A , Agarwal M . Therapy related chronic myeloid Leukemia (trCML) or non‐ therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B‐cell lymphoma (DLBCL): a case report and review of literature. Am J Med Case Rep. 2016;4:1‐9.)
Louis R , Gupta SK , Jain S , Mehta A , Agarwal M . Therapy related chronic myeloid Leukemia (trCML) or non‐ therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B‐cell lymphoma (DLBCL): a case report and review of literature. Am J Med Case Rep. 2016;4:1‐9.Louis R , Gupta SK , Jain S , Mehta A , Agarwal M . Therapy related chronic myeloid Leukemia (trCML) or non‐ therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B‐cell lymphoma (DLBCL): a case report and review of literature. Am J Med Case Rep. 2016;4:1‐9., Louis R , Gupta SK , Jain S , Mehta A , Agarwal M . Therapy related chronic myeloid Leukemia (trCML) or non‐ therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B‐cell lymphoma (DLBCL): a case report and review of literature. Am J Med Case Rep. 2016;4:1‐9.
M. Sonbol, T. Halfdanarson, T. Hilal (2020)
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.JAMA oncology
Ulrike Garske-Román, M. Sandström, Katarzyna Baron, Lars Lundin, P. Hellman, S. Welin, S. Johansson, T. Khan, H. Lundqvist, B. Eriksson, A. Sundin, D. Granberg (2018)
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicityEuropean Journal of Nuclear Medicine and Molecular Imaging, 45
A. Erçalışkan, A. Eşkazan (2018)
The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemiaCancer, 124
T. Brabander, W. Zwan, J. Teunissen, B. Kam, R. Feelders, W. Herder, C. Eijck, G. Franssen, E. Krenning, D. Kwekkeboom (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsClinical Cancer Research, 23
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
(2018)
incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors
( Tsushima H , Iwanaga M , Miyazaki Y . Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012;95(3):232‐238.22370711)
Tsushima H , Iwanaga M , Miyazaki Y . Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012;95(3):232‐238.22370711Tsushima H , Iwanaga M , Miyazaki Y . Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012;95(3):232‐238.22370711, Tsushima H , Iwanaga M , Miyazaki Y . Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012;95(3):232‐238.22370711
G. Issa, H. Kantarjian, G. Gonzalez, G. Borthakur, G. Tang, W. Wierda, K. Sasaki, N. Short, F. Ravandi, T. Kadia, K. Patel, R. Luthra, A. Ferrajoli, G. Garcia-Manero, M. Rios, S. Dellasala, E. Jabbour, J. Cortes (2017)
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.Blood, 130 19
(2019)
Safety and outcomes of 177LuDOTATATE for neuroendocrine tumours: experience in New South Wales, Australia
E. Demirci, L. Kabasakal, Türkay Toklu, M. Ocak, O. Şahin, Nalan Alan-Selçuk, A. Araman (2018)
177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival updateNuclear Medicine Communications, 39
E. Raymond, L. Dahan, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, Denis Smith, A. Vinik, Jen‐Shi Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Cutsem, S. Patyna, D. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski (2011)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.The New England journal of medicine, 364 6
( Iriyama N , Tokuhira M , Takaku T , et al. Incidences and outcomes of therapy‐related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group. Leuk Res. 2017;54:55‐58.28109974)
Iriyama N , Tokuhira M , Takaku T , et al. Incidences and outcomes of therapy‐related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group. Leuk Res. 2017;54:55‐58.28109974Iriyama N , Tokuhira M , Takaku T , et al. Incidences and outcomes of therapy‐related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group. Leuk Res. 2017;54:55‐58.28109974, Iriyama N , Tokuhira M , Takaku T , et al. Incidences and outcomes of therapy‐related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group. Leuk Res. 2017;54:55‐58.28109974
( Sonbol MB , Halfdanarson TR , Hilal T . Assessment of Therapy‐Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol [published online ahead of print, 2020 Apr 16]. 2020;6(7):1086–1092.32297906)
Sonbol MB , Halfdanarson TR , Hilal T . Assessment of Therapy‐Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol [published online ahead of print, 2020 Apr 16]. 2020;6(7):1086–1092.32297906Sonbol MB , Halfdanarson TR , Hilal T . Assessment of Therapy‐Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol [published online ahead of print, 2020 Apr 16]. 2020;6(7):1086–1092.32297906, Sonbol MB , Halfdanarson TR , Hilal T . Assessment of Therapy‐Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol [published online ahead of print, 2020 Apr 16]. 2020;6(7):1086–1092.32297906
J. Rowley (1973)
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 243
Cancer Reports – Wiley
Published: Oct 1, 2020
Keywords: ; ; ; ;
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.